Centre for Rare Disorders, Oslo University Hospital, Postboks 4950 Nydalen, 0424, Oslo, Norway.
Department of Surgery, Inflammation Medicine and Transplantation, Section of Nephrology, Oslo University Hospital, Rikshospitalet HF, Oslo, Norway.
Orphanet J Rare Dis. 2021 Oct 12;16(1):427. doi: 10.1186/s13023-021-02066-y.
Fabry disease (FD) is an X-linked lysosomal storage disorder characterized by multiorgan dysfunction. Since individuals with FD usually experience progressive clinical disease manifestations, their health-related quality of life (HRQOL) is expected to change over time. However, there is limited longitudinal research examining HRQOL outcomes in individuals with FD. We aimed to: assess longitudinal outcomes in HRQOL in adults with FD; examine the physical- and mental HRQOL trajectories at the initial registration (baseline), 3-5 year, and 7-13 year follow-ups; and evaluate the possible associations of age, sex and medical complications with the physical- and mental HRQOL trajectories.
Forty-three individuals with FD (53% female) who were aged 18 to 81 years at baseline attended clinical follow-up visits between 2006 and 2020. Medical records were extracted retrospectively. Demographics and the 36-item Short-Form Health Survey (SF-36) were recorded at scheduled visits, except for the last data collection which was prospectively obtained in 2020. The physical (PCS) and mental (MCS) composite scores (SF-36) were chosen as outcome measures.
The eight SF-36 domain scores were stable over a span of 13 years, and only physical- and social functioning domains worsened clinically over this follow-up period. Mean baseline SF-36 domain scores were all significantly lower (decreased HRQOL) in the FD sample compared with Norwegian population norms. Two hierarchical linear models were run to examine whether demographics and medical complications (measured at the last clinical visit) predicted physical and mental HRQOL trajectories. Age above 47 years (p < 0.001), male sex (p = 0.027), small fibre neuropathy (p < 0.001), renal dysfunction (p < 0.001), and cerebrovascular events (p = 0.003) were associated with lower HRQOL over time. No significant interactions were found between the time of follow up and the abovementioned predictors of HRQOL.
Overall HRQOL trajectories remained stable between baseline, 3-5 year, and 7-13 year follow-ups, with the majority of individuals reporting decreased physical and mental HRQOL. Medical complications in combination with older age and male sex are important predictors of lower HRQOL in FD. Awareness of this relationship is valuable both for health care providers and for patients. The findings provide indicators that can guide treatment decisions to improve physical and mental HRQOL outcomes.
法布里病(FD)是一种 X 连锁溶酶体贮积症,其特征为多器官功能障碍。由于 FD 患者通常经历进行性临床疾病表现,因此预计他们的健康相关生活质量(HRQOL)会随时间而变化。然而,对于 FD 患者的 HRQOL 结果,纵向研究有限。我们旨在:评估 FD 成人的 HRQOL 纵向结局;检查初始注册(基线)、3-5 年和 7-13 年随访时的身体和心理 HRQOL 轨迹;并评估年龄、性别和医疗并发症与身体和心理 HRQOL 轨迹的可能关联。
43 名 FD 患者(53%为女性)在基线时年龄为 18-81 岁,于 2006 年至 2020 年期间接受临床随访。回顾性提取病历。除最后一次数据采集为 2020 年前瞻性获得外,在预定就诊时记录人口统计学和 36 项简明健康调查问卷(SF-36)。选择身体(PCS)和心理(MCS)综合评分(SF-36)作为结局测量指标。
8 项 SF-36 领域评分在 13 年的时间跨度内保持稳定,只有身体和社会功能领域在这段随访期间出现临床恶化。FD 样本的基线 SF-36 领域评分均明显低于挪威人群正常值(降低 HRQOL)。进行了两个层次线性模型,以检验人口统计学和医疗并发症(在最后一次临床就诊时测量)是否可以预测身体和心理 HRQOL 轨迹。47 岁以上年龄(p<0.001)、男性(p=0.027)、小纤维神经病(p<0.001)、肾功能障碍(p<0.001)和脑血管事件(p=0.003)与随时间推移 HRQOL 降低相关。在 HRQOL 的上述预测因子与随访时间之间未发现显著的交互作用。
总体 HRQOL 轨迹在基线、3-5 年和 7-13 年随访之间保持稳定,大多数患者报告身体和心理 HRQOL 下降。FD 中的医疗并发症加上年龄较大和男性是 HRQOL 降低的重要预测因素。了解这种关系对医疗保健提供者和患者都很有价值。研究结果为改善身体和心理 HRQOL 结果的治疗决策提供了指标。